2022 was not a good year for BB Biotech. The NAV fell by 11 percent, the holding remained a loss of 358 million Swiss francs. Last year the deficit was 05 million Swiss francs. You remain loyal to the dividend policy. The yield is around 5 percent and investors pay 2.85 Swiss francs per share. In the last quarter of 2022, BB Biotech did not make any new investments. However, some stocks were added and profit taken. From BB Biotech’s perspective, 2023 will be better again. Different impulses are seen for the industry. There should be affiliate research results, and new products are also expected to hit the market. Analysts at Baader reaffirm an „outperform” rating on BB Biotech stock. The target price is still CHF 6 .20. The company primarily serves small and medium-sized American companies in the biotechnology industry. Analysts like it. Additionally, BB Biotech’s overall track record is positive. , shares of BB Biotech (WKN: A0NFN3 , ISIN: CH0038389992 , Chart ) are up 0.9 percent at 56.90 Swiss francs.